FSHD drug receives fast track designation

Acceleron Pharma has announced the US Food and Drug Administration (FDA) has granted Fast Track Designation to ACE-083, for the treatment of facioscapulohumeral muscular dystrophy (FSHD). This status will help speed up the development and regulatory review process of the drug.

ACE-083 is currently being evaluated in a Phase 2 trial in individuals with FSHD.

For more information, please read Acceleron’s press release.


To find out more about the latest research in facioscapulohumeral  muscular dystrophy, please contact our Research team at research@musculardystrophyuk.org.